Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease
- PMID: 7512900
- DOI: 10.2165/00003495-199447020-00003
Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease
Abstract
The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs of joint inflammation, whilst at the same time causing significant reductions in the laboratory measures of the acute phase response is undoubtedly confirmed by meta-analysis of several therapeutic trials of these agents. Whether or not these agents can influence outcome, usually assessed in terms of radiological progression, is more contentious. Furthermore, their toxicity in long term use is not inconsiderable. However, newer agents may play a more important part in therapy in the future. Such therapy can be designed to specifically interfere with the abnormalities of the immune system which characterise rheumatoid arthritis. Many of the agents reviewed have been successfully applied to animal models of arthritis but we still await large randomised controlled studies in humans to determine their clinical efficacy and toxicity. In view of the complexity of the immunological abnormalities in rheumatoid arthritis, it may be necessary to consider using a number of such agents in any particular patient. This should result in more rational therapy in rheumatoid arthritis.
Similar articles
-
[Indication for a modern therapy of rheumatoid arthritis].Clin Ter. 1998 Mar-Apr;149(2):135-8. Clin Ter. 1998. PMID: 9780479 Italian.
-
Treatment of severe rheumatoid arthritis.Ann Clin Res. 1983 Apr;15(2):80-7. Ann Clin Res. 1983. PMID: 6349514 Clinical Trial.
-
[Extracorporeal therapy of rheumatoid arthritis].Ter Arkh. 2001;73(6):70-5. Ter Arkh. 2001. PMID: 11521529 Review. Russian. No abstract available.
-
The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Expert Rev Clin Immunol. 2017 Jun;13(6):535-551. doi: 10.1080/1744666X.2017.1295850. Epub 2017 Mar 3. Expert Rev Clin Immunol. 2017. PMID: 28494214 Review.
-
Strategies for medical treatment based on current understanding of the pathogenesis of rheumatoid arthritis.Clin Orthop Relat Res. 1984 Jan-Feb;(182):31-6. Clin Orthop Relat Res. 1984. PMID: 6319061 Review.
Cited by
-
A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients.Pharm Res. 1999 Oct;16(10):1608-15. doi: 10.1023/a:1018969024101. Pharm Res. 1999. PMID: 10554105 Clinical Trial.
-
Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.Clin Pharmacokinet. 1994 Dec;27(6):462-85. doi: 10.2165/00003088-199427060-00005. Clin Pharmacokinet. 1994. PMID: 7882636 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical